EYEG Share Price | Kiora Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Kiora Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Kiora Pharmaceuticals, Inc. has a market capitalization of 8.95 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Kiora Pharmaceuticals reported net sales of 0.02 million and a net profit of -12.04 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 25.76 million and total assets of 36.48 million.

Q: What does Kiora Pharmaceuticals, Inc. do?

Overview:Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 8.95 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -44.68% Price to Book: 0.38 Contact Details:Address: 271 Waverley Oaks Rd Ste 108, WALTHAM MA: 02452-8475 Tel: 1 781 7889043 Website: http://www.eyegatepharma.com/

Q: Is Kiora Pharmaceuticals, Inc. overvalued or undervalued?

As of 9 May 2025, Kiora Pharmaceuticals, Inc. has moved from an attractive valuation grade to one that does not qualify. The company appears to be overvalued given its current financial metrics. Notably, the Price to Book Value stands at 0.40, while the EV to EBITDA is at 1.17. The Return on Capital Employed (ROCE) is exceptionally high at 1262.96%, but this is misleading as the company is loss-making, reflected in its negative P/E ratio and ROE of -44.68%.In comparison to its peers, Kiora Pharmaceuticals has a valuation score of -0.8451, while SeqLL, Inc. is at -1.5744 and Hoth Therapeutics, Inc. at -1.7844, indicating that Kiora is relatively better positioned among its peers despite not qualifying for a positive valuation. The recent stock performance shows a decline of 15.86% over the past year, contrasting with a 10.26% gain in the S&P 500, reinforcing the notion that the stock is overvalued in the current market context.

Q: Is Kiora Pharmaceuticals, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Kiora Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly chart. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. The OBV shows a mildly bullish signal weekly but no trend monthly.In terms of performance, Kiora has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -19.68% versus the S&P 500's 12.22%, and a one-year return of -26.78% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by bearish signals in the weekly MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

79.4 k

Shareholding (Sep 2025)

FII

8.45%

Held by 5 FIIs

DII

90.26%

Held by 1 DIIs

Promoter

0.00%

How big is Kiora Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Kiora Pharmaceuticals, Inc. has a market capitalization of 8.95 million, with net sales of 0.02 million and a net profit of -12.04 million over the latest four quarters. The company reported shareholder's funds of 25.76 million and total assets of 36.48 million as of Dec 24.

View full answer

What does Kiora Pharmaceuticals, Inc. do?

22-Jun-2025

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapeutics and drug delivery systems for eye diseases. It has a market cap of $8.95 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Kiora Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Kiora Pharmaceuticals, Inc. includes Paul Chaney (Independent Chairman), Stephen From (CEO), Steven Boyd, Keith Maher, Morton Goldberg, Thomas Hancock, and Bernard Malfroy-Camine (all Independent Directors). They oversee the company's strategic direction and operations.

View full answer

Is Kiora Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2025, Kiora Pharmaceuticals is considered overvalued with a valuation score of -0.8451, despite a high ROCE of 1262.96%, negative P/E ratio, and a 15.86% decline in stock performance over the past year compared to a 10.26% gain in the S&P 500.

View full answer

Is Kiora Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Kiora Pharmaceuticals has a mildly bearish technical trend, indicated by bearish weekly MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -19.68%.

View full answer

Compare Kiora Pharmaceuticals, Inc. with Similar Stocks

Cyclacel Pharmaceuticals, Inc.Jaguar Health, Inc.Evoke Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.86

Return on Equity

-43.23%

Price to Book

0.36

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-33.54%

6 Months

-41.76%

1 Year

-49.01%

2 Years

-69.41%

3 Years

-98.56%

4 Years

-99.87%

5 Years

-99.89%

Kiora Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-6.27%

EBIT to Interest (avg)

-7.32

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.42

Tax Ratio

22.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

48.17%

ROCE (avg)

35.43%

ROE (avg)

3.98%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.40

EV to EBIT

1.16

EV to EBITDA

1.17

EV to Capital Employed

14.66

EV to Sales

-14.66

PEG Ratio

Dividend Yield

ROCE (Latest)

1262.96%

ROE (Latest)

-44.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (1.29%)

Foreign Institutions

Held by 5 Foreign Institutions (8.45%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 100.00% vs 41.38% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-2.70",
          "chgp": "7.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.70",
          "val2": "-0.90",
          "chgp": "288.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "-3.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 128.80% vs 8.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.70",
          "val2": "-8.60",
          "chgp": "131.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "-3.90",
          "chgp": "69.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.60",
          "val2": "-12.50",
          "chgp": "128.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "164.50%",
          "val2": "0.00%",
          "chgp": "16.45%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.50

-2.70

7.41%

Interest

0.00

Exceptional Items

1.70

-0.90

288.89%

Consolidate Net Profit

0.00

-3.40

100.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 100.00% vs 41.38% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

16.00

0.00

Operating Profit (PBDIT) excl Other Income

2.70

-8.60

131.40%

Interest

0.00

Exceptional Items

-1.20

-3.90

69.23%

Consolidate Net Profit

3.60

-12.50

128.80%

Operating Profit Margin (Excl OI)

164.50%

0.00%

16.45%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 128.80% vs 8.09% in Dec 2023

All Annual Results

Company CV

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Company Coordinates

Company Details

271 Waverley Oaks Rd Ste 108 , WALTHAM MA : 02452-8475

Tel: 1 781 7889043

http://www.eyegatepharma.com/

Registrar Details

Kiora Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Kiora Pharmaceuticals, Inc.?

Watch in Real-Time

What does Kiora Pharmaceuticals, Inc. do?

Who are in the management team of Kiora Pharmaceuticals, Inc.?

Is Kiora Pharmaceuticals, Inc. overvalued or undervalued?

Is Kiora Pharmaceuticals, Inc. technically bullish or bearish?

Compare Kiora Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Kiora Pharmaceuticals, Inc.

Company Coordinates